Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2018

View Archived Issues

Chugai reflects on accomplishments of fourth quarter 2017

Astellas updates regulatory and clinical developments of third quarter of fiscal 2017

IRLAB provides update on its lead development programs, IRL-752 and IRL-790

Ozempic and Fiasp launched in the U.S.

Topline results from phase IIb study of EGP-437

Phase III ADVANCE study of Rolontis meets primary endpoint

SapVax announces its most recent achievements

Acticor Biotech's phase I study of ACT-017 meets endpoints

FDA expands indication for AMAG's Feraheme

TBX15 identified as predictor of poor survival in HCC patients

Oricula Therapeutics cleared to begin clinical testing of ORC-13661 in U.S.

Paratek Pharmaceuticals submits omadacycline NDAs in U.S.

Survival endpoint met with nab-paclitaxel regimen in biliary tract cancer trial

Jupiter Orphan Therapeutics preparing INDs for Jotrol

FDA clears Trethera's TRE-515 IND

Fibrocell Science submits IND for gene therapy candidate for scleroderma

EMA accepts Epidiolex MAA for review

V1B receptor antagonism may enhance alcohol dependency treatment

First patient dosed in phase Ib/II aldoxorubicin combination study

Redx Pharma initiates phase I/IIa trial of RXC-004 in hard to treat cancers

Lilly identifies new JAK1 inhibitors

Medshine Discovery patents nitroimidazole derivatives

New isocitrate dehydrogenase inhibitors described by Nanjing Sanhome Pharmaceutical

Italfarmaco divulges novel benzo-N-hydroxy amide compounds

Incyte discovers new PD-1/PD-L1 interaction inhibitors